News
9h
TipRanks on MSNGilead Sciences’ Promising Phase 3 Study in Lung Cancer Treatment
Gilead Sciences (($GILD)) announced an update on their ongoing clinical study. Gilead Sciences is currently conducting a Phase 3 clinical study ...
CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...
Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...
Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...
Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.
The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could ...
Gilead has become the latest pharma to strengthen its in-vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. | Gilead has become the latest ...
The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.
Gilead exceeded market expectations in the second quarter, reporting earnings per share of $2.01 on revenue of $7.08 billion. Profitability metrics impressed with a 21.86% margin and a return on ...
Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading below its intrinsic value. See more.
Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results